An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins: Structures, functions and drug development

被引:13
作者
Chen, Shuai
Luo, Haibin
Chen, Lili
Chen, Jing
Shen, Jianhua
Zhu, Weiliang
Chen, Kaixian
Shen, Xu [1 ]
Jiang, Hualiang
机构
[1] Chinese Acad Sci, Grad Sch, Shanghai Inst Biol Sci,Drug Discovery & Design Ct, Shanghai Inst Mat Med,State Key Lab Drug Res, Shanghai 201203, Peoples R China
[2] E China Univ Sci & Technol, Sch Pharm, Shanghai 200237, Peoples R China
关键词
atypical pneumonia; SARS Coronavirus; SARS-CoV genome-encoded major proteins; structural and functional characterization; inhibitor design and screening; structure-based drug development;
D O I
10.2174/138161206779010459
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A severe atypical pneumonia designated as severe acute respiratory syndrome (SARS) by The World Health Organization broke out in China and menaced to more than other 30 countries between the end of the year 2002 and June of the year 2003. A novel coronavirus called severe acute respiratory syndrome coronavirus (SARS-CoV) has been recently identified as the etiological agent responsible for the infectious SARS disease. Based on extensively scientific cooperation and almost two-year's studies, remarkable achievements have been made in the understanding of the phylogenetic property and the genome organization of SARS-CoV, as well as the detailed characters of the major proteins involved in SARS-CoV life cycle. In this review, we would like to summarize the substantial scientific progress that has been made towards the structural and functional aspects of SARS-CoV associated key proteins. The progress focused oil the corresponding key proteins' structure-based drug and vaccine developments has been also highlighted. The concerted and cooperative response for the treatment of the SARS disease has been proved to be a triumph of global public health and provides a new paradigm for the detection and control of future emerging infectious disease threats.
引用
收藏
页码:4539 / 4553
页数:15
相关论文
共 106 条
[71]   Structural maturation of the transmissible gastroenteritis coronavirus [J].
Salanueva, IJ ;
Carrascosa, JL ;
Risco, C .
JOURNAL OF VIROLOGY, 1999, 73 (10) :7952-7964
[72]  
Shen X, 2003, ACTA PHARMACOL SIN, V24, P505
[73]   Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme - Defining the extra domain as a new target for design of highly specific protease inhibitors [J].
Shi, JH ;
Wei, Z ;
Song, JX .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (23) :24765-24773
[74]   Heterogeneous nuclear ribonucleoprotein A1 regulates RNA synthesis of a cytoplasmic virus [J].
Shi, ST ;
Huang, PY ;
Li, HP ;
Lai, MMC .
EMBO JOURNAL, 2000, 19 (17) :4701-4711
[75]  
SIDDEL SG, 1995, CORONAVIRIDAE
[76]   Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore pointst [J].
Sirois, S ;
Wei, DQ ;
Du, QS ;
Chou, KC .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2004, 44 (03) :1111-1122
[77]   Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage [J].
Snijder, EJ ;
Bredenbeek, PJ ;
Dobbe, JC ;
Thiel, V ;
Ziebuhr, J ;
Poon, LLM ;
Guan, Y ;
Rozanov, M ;
Spaan, WJM ;
Gorbalenya, AE .
JOURNAL OF MOLECULAR BIOLOGY, 2003, 331 (05) :991-1004
[78]   Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein [J].
Spiga, O ;
Bernini, A ;
Ciutti, A ;
Chiellini, S ;
Menciassi, N ;
Finetti, F ;
Causarono, V ;
Anselmi, F ;
Prischi, F ;
Niccolai, N .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 310 (01) :78-83
[79]  
Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
[80]   Molecular cloning, expression, purification, and mass spectrometric characterization of 3C-like protease of SARS coronavirus [J].
Sun, HF ;
Luo, HB ;
Yu, CY ;
Sun, T ;
Chen, J ;
Peng, SY ;
Qin, J ;
Shen, JH ;
Yang, YM ;
Xie, YH ;
Chen, KX ;
Wang, Y ;
Shen, X ;
Jiang, HL .
PROTEIN EXPRESSION AND PURIFICATION, 2003, 32 (02) :302-308